Pexipepimut-S Drug Asset Due Diligence Report 2026

This Pexipepimut-S Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Pexipepimut-S can convert its Shared antigen vaccine, Liposomal Drug profile and HPV E6 x HPV E7 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Pexipepimut-S (query alias: Pexipepimut-S)
Modality / target	Shared antigen vaccine, Liposomal Drug; HPV E6 x HPV E7; E7 inhibitors, HPV E6 inhibitors
Highest global status	Phase 2
Originator	PDS Biotechnology Corp.
Active developers	National Cancer Institute, PDS Biotechnology Corp.

The MCP disease footprint includes Head and neck cancer metastatic, HPV positive oropharyngeal squamous cell carcinoma, Recurrent Head and Neck Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07090174	Phase 2	Withdrawn	0	Primary endpoint not disclosed in English source
NCT06790966	Phase 3	Terminated	12	Primary endpoint not disclosed in English source
NCT05232851	Phase 1/2	Active, not recruiting	20	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Stimulating Immune Response With Neoadjuvant Human Papilloma Virus (HPV)-16 Specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)

Phase 1/2; n=20; evaluation: Not stated in English source. Reported fields: Proportion of Pathologic and Human Papillomavirus Cell-free Tumor Deoxyribonucleic Acid (ctHPVDNA) Response = 0.5 % ; Proportion of Pathologic and Human Papillomavirus Cell-free Tumor Deoxyribonucleic Acid (ctHPVDNA) Response = 0 %

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Phase 2; n=53; evaluation: Positive. Reported fields: mOS(CPS ≥ 1) = 39.3 Month (95%CI, 23.9 - NE)

Versatile-002: Overall survival of HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma patients treated with T cell stimulating immunotherapy PDS0101 and pembrolizumab.

Phase 2; n=53; evaluation: Positive. Reported fields: mOS = 30 Month ( 23.9 - NE); mOS = 29.5 Month ( 15.3 - NE)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Pexipepimut-S addresses Head and neck cancer metastatic, HPV positive oropharyngeal squamous cell carcinoma, Recurrent Head and Neck Carcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Shared antigen vaccine, Liposomal Drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: HPV E6 x HPV E7.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HPV E6 x HPV E7 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Particulate vaccine formulations”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO